INLAND IMAGING Introduces Illuccix®: a Radioactive Diagnostic Agent for PET-CT (positron emission tomography)

Improves the Detection and Treatment of Prostate Cancer. — May 30, 2022

Recently approved for use by the FDA, the availability of this new agent helps improve access to more advanced and detailed imaging for patients facing diagnosis and treatment of prostate cancer.

“The approval of Illuccix will give patients considerably improved access to PSMA-PET imaging. PSMA PET can be used for initial staging of prostate cancer or evaluating recurrent disease,” said David Mariner, Director of Nuclear Medicine and PetCT at Inland Imaging. “PSMA-PET will also
be used in conjunction with a new prostate cancer therapy, Lu-177 PSMA, that we anticipate starting later this summer.”

Illuccix is the first commercially available FDA-approved product to enable wide accessibility to PSMA-PET imaging for physicians and eligible patients in the region.

“This product offers a level of sensitivity and specificity that is superior to regular FDG PET for most prostate cancer patients  and may help us provide better patient experiences, and outcomes, as a result,” said Dr. Irene Cruite, a radiologist at Inland Imaging specializing in Nuclear Medicine.

“Improved imaging can provide physicians with the insights to more accurately determine the current state of disease and the most appropriate treatment
pathway. It gives patients access to a specific and sensitive imaging tool for the detection of prostate cancer throughout the body.”

According to the American Cancer Society, prostate cancer is the second leading cancer in men in the United States with nearly 250,000 cases and more than 34,500 deaths from the disease in 2021 — a significantly higher incidence than either lung cancer (119,000 new cases) or bowel cancer (80,000 new cases). More than 800,000 U.S. men are estimated to be living with prostate cancer today.